Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354097 | 0.80 | KMT2A (0.34) | L3MBTL1 | |
| SCHEMBL1427291 | 0.77 | ACHE (0.35) | — | |
| SCHEMBL29219229 | 0.77 | — | — | |
| SCHEMBL28394743 | 0.76 | ACHE (0.35) | — | |
| SCHEMBL7244739 | 0.74 | GAA (0.44) | ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL31752129 | 0.73 | PDE4A (0.31) | — | |
| SCHEMBL692875 | 0.72 | — | — | |
| SCHEMBL561256 | 0.71 | — | — | |
| SCHEMBL7489361 | 0.69 | GRM4 (0.39) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL155502 | 0.68 | HRH3 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216045-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | American Cynamid Company (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001022969-A2 | VASOPRESSIN AGONIST FORMULATION AND PROCESS | AMERICAN CYNAMID COMPANY (US) | 2001-04-05 | — | — | WO | claimed |
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-06 | — | — | US | disclosed |
| EP-4464693-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| CN-118632836-A | Novel aminobenzene derivative having cancer cell growth inhibitory effect and preventive or therapeutic pharmaceutical composition containing the same as active ingredient | 株式会社大熊制药 | 2024-09-10 | — | — | CN | disclosed |
| CN-118239931-A | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-114269432-B | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117279636-A | Methods and compounds for modulating myotonic muscular dystrophy type 1 | 设计治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023136645-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 주식회사 대웅제약 | 2023-07-20 | — | — | WO | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-6511974-B1 | Non-peptidic and have good oral bioavailability, specific vasopressin V2 agonists, therefore do not raise blood pressure | WYETH | 2003-01-28 | — | — | US | disclosed |
| CN-1391476-A | Vasopressin agonist formulation and process | AMERICAN CYANAMID CO (US) | 2003-01-15 | — | — | CN | disclosed |
| EP-1242426-A1 | GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001038332-A1 | GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| CN-1272111-A | Tricyclic vasopressin agonists | AMERICAN HOME PROD (US) | 2000-11-01 | — | — | CN | disclosed |
| EP-1000062-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006409-A1 | TRICYCLIC VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | MKI67, CCNB1, ALDH7A1 | ALDH1A1 211/4885HTT 4601/4885SMN1; SMN2 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.